This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation
by Zacks Equity Research
With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.
Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study
by Zacks Equity Research
With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and Eisai have decided to close the study.
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
by Zacks Equity Research
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
by Zacks Equity Research
Pacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label expansion is set to boost sales in future quarters.
Alaunos (TCRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Alaunos (TCRT) closed at $0.60 in the latest trading session, marking a -1.64% move from the prior day.
Alaunos (TCRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Alaunos (TCRT) closed at $0.50, marking a +1.02% move from the previous day.
Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.
Alaunos (TCRT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Alaunos (TCRT) closed the most recent trading day at $0.55, moving -0.54% from the previous trading session.
Alaunos (TCRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Alaunos (TCRT) closed at $0.60 in the latest trading session, marking a +0.81% move from the prior day.
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.
Alaunos (TCRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Alaunos (TCRT) closed at $0.64 in the latest trading session, marking a -1.54% move from the prior day.
Alaunos (TCRT) Stock Moves -0.75%: What You Should Know
by Zacks Equity Research
In the latest trading session, Alaunos (TCRT) closed at $0.66, marking a -0.75% move from the previous day.
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Agios Pharmaceuticals (AGIO) and Alaunos (TCRT) have performed compared to their sector so far this year.
Alaunos (TCRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Alaunos (TCRT) closed at $0.70, marking a -1.71% move from the previous day.
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
by Zacks Equity Research
Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Here's Why Ziopharm (TCRT) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Ziopharm (TCRT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
After Plunging 42% in 4 Weeks, Here's Why the Trend Might Reverse for Ziopharm (TCRT)
by Zacks Equity Research
Ziopharm (TCRT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
New Strong Buy Stocks for November 18th
by Zacks Equity Research
VIRC, TCRT, AINC, CWEN and WHF have been added to the Zacks Rank #1 (Strong Buy) List on November 18, 2022.
Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
What Makes Ziopharm (TCRT) a New Buy Stock
by Zacks Equity Research
Ziopharm (TCRT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.